EMBECTA CORP. (EMBC) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Bernstein Liebhard LLP is investigating potential breaches of fiduciary duty by certain directors and officers of Embecta Corp. (NASDAQ: EMBC). The investigation aims to determine if the Company's leadership acted in the best interests of shareholders and if legal remedies are available. Shareholders who purchased shares before November 25, 2025, are encouraged to contact the firm for more information.
EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop
Embecta Corp. (EMBC) is facing a securities fraud class action lawsuit filed by Bleichmar Fonti & Auld LLP. The lawsuit alleges that Embecta misled investors about the strength of its insulin pen needle product category, leading to a 57.8% stock drop on May 5, 2026, after the company announced disappointing Q2 2026 results and reduced its quarterly dividend. Investors have until August 17, 2026, to seek to be appointed lead plaintiff in the case.
EMBC Stock News: Embecta Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 57% Stock Drop
Embecta Corp. (NASDAQ: EMBC) is being sued for securities fraud after its stock dropped over 57% due to alleged misrepresentations about the strength of its insulin pen needle product category. A class action lawsuit has been filed, claiming the company failed to disclose significant competition and market softness despite touting the product's resilience. The lawsuit follows Embecta's Q2 2026 results, which revealed a substantial share loss and a reduction in its quarterly dividend.
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors that the deadline to seek lead plaintiff status in a federal securities class action lawsuit is August 17, 2026. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance and pen needle business, which led to a significant stock price drop of over 57.8% on May 5, 2026, after the company missed its second-quarter guidance and lowered its fiscal year 2026 outlook. Investors who purchased EMBC securities between November 25, 2025, and May 4, 2026, are encouraged to contact the law firm to discuss their legal options.
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made materially false and misleading statements, particularly regarding its financial guidance and pen needle business, leading to investor harm. The firm is encouraging affected investors to join the case before the lead plaintiff deadline of August 17, 2026.
EMBC Deadline: EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit
The Rosen Law Firm is reminding investors who purchased Embecta Corp. (NASDAQ: EMBC) common stock between November 25, 2025, and May 4, 2026, about the August 17, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its fiscal results and guidance, particularly concerning its pen needle business, leading to investor damages when the true details emerged. Investors are encouraged to contact the firm to potentially join the class action and act as lead plaintiff.
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has announced a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged securities fraud, encouraging investors who purchased shares between November 25, 2025, and May 4, 2026, to contact the firm regarding lead plaintiff appointments. The lawsuit claims Embecta made misleading statements about its fiscal guidance, failing to disclose known headwinds in the pen needle market that would impact its performance. Investors who suffered losses have until August 17, 2026, to participate in the case.
EMBC Court News: Embecta Securities Fraud Class Action
A securities fraud class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and its executives due to a significant stock drop of over 57%. This drop followed the company allegedly misleading investors about the strength of its insulin pen needle product category, facing market softness and increased competition. Investors have until August 17, 2026, to apply to be lead plaintiffs in the lawsuit.
Embecta Corp. Sued for Securities Law Violations - FINAL DEADLINE TODAY - EMBC
DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged securities law violations between November 25, 2025, and May 4, 2026. The lawsuit claims Embecta made false and misleading statements regarding its fiscal guidance despite being aware of challenges in the pen needle market. Investors who suffered losses and purchased shares during this period are encouraged to contact DJS Law Group by the final deadline, August 17, 2026, to potentially participate in the lawsuit.
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of an approaching securities class action lawsuit deadline on August 17, 2026. The lawsuit alleges that Embecta made false and misleading statements regarding its financial performance, specifically its pen needle business, which led to a significant stock price drop on May 5, 2026. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to contact the law firm to discuss their legal options or to seek appointment as lead plaintiff.
Embecta Corp. (EMBC) Notice of August 17, 2026 Deadline in Class Action Lawsuit – Hagens Berman
Hagens Berman is investigating Embecta Corp. (EMBC) following a class action lawsuit alleging the company misrepresented the stability of its insulin pen needle business, leading to substantial investor losses. The lawsuit claims Embecta's assurances of a "stable" business were false, as the company faced significant competitive share loss and market volume softness, culminating in a massive revenue decline, a 43% cut in EPS guidance, and a 93% dividend reduction, causing a 57.8% stock plummet. Investors who purchased EMBC stock between November 25, 2025, and May 4, 2026, are encouraged to contact Hagens Berman by the August 17, 2026 deadline.
Kaplan Fox Continues to Remind Embecta Corp. (NASDAQ: EMBC) Investors of the Lead Plaintiff Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP is reminding investors of Embecta Corp. (NASDAQ: EMBC) that the lead plaintiff deadline for a class action lawsuit is August 17, 2026. The lawsuit, filed on behalf of investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, alleges that the company's management knew about segment weakness, particularly in the U.S. pen needle market, that would impact its revenue guidance and Q2 2026 results. This follows a significant drop in Embecta's stock price after it reported disappointing Q2 2026 financial results and reduced its fiscal 2026 revenue guidance.
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has announced a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) and its officers, alleging violations of federal securities laws. The lawsuit claims that Embecta made false and misleading statements regarding its business, operations, and prospects between November 25, 2025, and May 4, 2026, specifically concerning its pen needle business and financial guidance. Investors who suffered losses are encouraged to join the case, with a lead plaintiff deadline of August 17, 2026.
Kaplan Fox Continues to Remind Embecta Corp. (NASDAQ: EMBC) Investors of the Lead Plaintiff Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP is reminding investors of the upcoming lead plaintiff deadline, August 17, 2026, in a class action lawsuit against Embecta Corp. The lawsuit, filed on behalf of investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, alleges that the company misrepresented its financial outlook. This reminder follows a significant drop in Embecta's stock price after it reported disappointing Q2 2026 financial results and reduced its fiscal 2026 revenue guidance.
EMBECTA CORP. DEADLINE MONDAY AUGUST 17th: Embecta Corp.
Bragar Eagel & Squire, P.C. has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased common stock between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements regarding its fiscal results, particularly its pen needle business, leading to a significant stock price drop after the company cut its 2026 fiscal guidance. Investors have until August 17, 2026, to apply to be appointed as lead plaintiff.
CLASS ACTION DEADLINE MONDAY NIGHT: Faruqi & Faruqi, LLP Reminds Embecta (EMBC) Investors of Securities Class Action Lawsuit Deadline on August 17, 2026
Faruqi & Faruqi, LLP is reminding Embecta (EMBC) investors of the August 17, 2026, deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that Embecta made misleading statements regarding its financial guidance, particularly concerning its pen needle business, leading to a significant stock price drop on May 5, 2026. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to contact the firm to discuss their legal options.
Kaplan Fox Alerts Embecta Corp. (NASDAQ: EMBC) Investors Who Suffered Losses to a Securities Class Action – Deadline is August 17, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit stems from Embecta's Q2 2026 financial results, which were significantly below expectations, leading to a over 57% drop in stock price. Investors who suffered losses have until August 17, 2026, to move the court to serve as a lead plaintiff.
EMBC Shareholder Alert: August 17, 2026 Lead Plaintiff Deadline in Embecta Corp. Securities Class Action - Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert regarding a securities class action against Embecta Corp. (NASDAQ: EMBC). Shareholders who purchased EMBC shares between November 25, 2025, and May 4, 2026, are encouraged to contact the firm, as the company is accused of making misleading statements about its financial health, specifically its pen needle business, prior to a significant stock price drop. The deadline to apply for lead plaintiff status is August 17, 2026.
Embecta Corp. SVP Elguicze purchases $93,360 in common stock
Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, recently purchased 20,000 shares of the company's common stock for $93,360. This insider purchase comes after a significant stock decline but a recent rebound, with the company trading at a low P/E ratio. The purchase follows strong Q3 fiscal 2026 results where Embecta exceeded analyst expectations for earnings and revenue, and raised its full-year guidance.
Insider Spends US$141k Buying More Shares In Embecta
Embecta's President, Devdatt Kurdikar, recently purchased US$141k worth of company stock at US$4.70 per share, increasing his holding by 3.9%. This is the largest insider purchase in the last year, suggesting optimism for the company's future, despite the overall insider ownership being relatively low at 1.6%. The article highlights that while insider ownership levels are modest, the recent buying activity indicates reasonable alignment and a positive outlook from insiders.
Bronstein, Gewirtz & Grossman LLC Urges Embecta Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) and its officers, alleging violations of federal securities laws. The lawsuit claims that Embecta made misleading statements regarding its business, operations, and prospects, specifically concerning its pen needle business and fiscal guidance, leading to investor harm. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to join the class action by August 17, 2026.
Kaplan Fox Continues to Alert Investors of Embecta Corp. (NASDAQ: EMBC) to a Class Action Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP is alerting investors of Embecta Corp. (NASDAQ: EMBC) about a class action lawsuit filed against the company. The lawsuit, on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026, alleges that Embecta misrepresented its financial outlook, leading to a significant stock drop after disappointing Q2 2026 results. Investors have until August 17, 2026, to move for lead plaintiff status.
Kaplan Fox Continues to Alert Investors of Embecta Corp. (NASDAQ: EMBC) to a Class Action Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP is alerting investors of Embecta Corp. (NASDAQ: EMBC) to a class action lawsuit with a lead plaintiff deadline of August 17, 2026. The lawsuit alleges that Embecta made misleading statements regarding its financial outlook, particularly concerning weakness in the U.S. pen needle market, which led to a significant drop in stock price after disappointing Q2 2026 results were announced. Investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, are encouraged to contact the firm.
EMBC 4-DAY DEADLINE ALERT: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - Hagens Berman
Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for alleged violations of federal securities laws, following a class action lawsuit claiming the company misrepresented the stability of its insulin pen needle business. Investors who suffered substantial losses between November 25, 2025, and May 4, 2026, have until August 17, 2026, to seek to become lead plaintiff. The lawsuit alleges Embecta's assurances of a "stable" business were false, as the company experienced significant competitive share loss and market volume softness, leading to a massive revenue decline and a drastic cut in its full-year guidance and quarterly dividend.
EMBC Shareholder Alert: Embecta Corp. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
SueWallSt has issued an alert to investors of Embecta Corp. (NASDAQ: EMBC) regarding a pending securities class action lawsuit. The lawsuit names CEO Devdatt Kurdikar and CFO Jacob P. Elguicze as individual defendants, alleging they disseminated misleading fiscal year 2026 guidance that caused shareholders to lose $5.35 per share. Investors who purchased EMBC shares between November 25, 2025, and May 4, 2026, are encouraged to contact SueWallSt, with a lead plaintiff deadline set for August 17, 2026.
EMBC Deadline: Rosen Law Firm Urges Embecta Corp. (NASDAQ: EMBC) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm has issued a reminder to investors regarding a class action lawsuit against Embecta Corp. (NASDAQ: EMBC). The lawsuit alleges that Embecta made misleading statements about its fiscal results and its pen needle business, causing investors to suffer damages. Shareholders who wish to act as lead plaintiff must file motions with the court by August 17, 2026.
Embecta director Robert Hombach acquires $223.8k in common stock
Embecta director Robert J. Hombach recently acquired 45,000 shares of the company's common stock for a total of $223,848. This insider purchase comes as the stock has seen a 36% surge in the past week, despite being significantly down from six months ago. The company also reported better-than-expected fiscal third-quarter results and raised its full-year operating margin guidance.
Embecta Corp. (EMBC) CFO purchases 20,000 shares in open-market trade
Embecta Corp.'s Senior Vice President and CFO, Jacob Elguicze, purchased 20,000 shares of the company's common stock on August 12, 2026, at a price of $4.668 per share. This open-market transaction increased his direct holdings to 309,138.604 shares. The purchase was not made under a Rule 10b5-1 plan, as indicated in the SEC Form 4 filing.
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) has reminded investors of a class action lawsuit against Embecta Corp. (EMBC) for alleged violations of securities laws. The lawsuit claims Embecta made false and misleading statements regarding its fiscal guidance for Q2 and full-year 2026, failing to disclose challenges in the pen needle market. Investors who purchased EMBC shares during the class period (November 25, 2025 to May 4, 2026) are encouraged to contact SBS by the August 17, 2026 deadline to discuss lead plaintiff opportunities.
EMBC Investors Have Opportunity to Lead Embecta Corp. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) for alleged securities fraud. The lawsuit claims Embecta made misleading statements regarding its fiscal guidance for Q2 and full-year 2026, knowing that market headwinds would impact performance. Investors who purchased EMBC shares between November 25, 2025, and May 4, 2026, are encouraged to contact SBS by the August 17, 2026, deadline to discuss potentially leading the lawsuit.
Kaplan Fox Encourages Embecta Corp. (NASDAQ: EMBC) Investors Seeking Recovery to Contact the Firm Before August 17, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. This action follows a significant drop in Embecta's stock price after the company reported disappointing Q2 fiscal 2026 results and reduced its revenue guidance. Investors who suffered losses are encouraged to contact Kaplan Fox before the lead plaintiff deadline of August 17, 2026.
EMBECTA CORP. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 17,
Bernstein Liebhard LLP reminds Embecta Corp. (NASDAQ: EMBC) investors that they have until August 17, 2026, to join a securities fraud class action lawsuit. The lawsuit alleges that Embecta made false and misleading statements about its business operations and financial stability between November 25, 2025, and May 4, 2026, leading to investor losses. Investors who purchased shares during this period and suffered losses are encouraged to contact the firm.
EMBC 6-DAY DEADLINE ALERT: Embecta Corp. Investors with
Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for alleged federal securities law violations after a class action lawsuit was filed. The lawsuit claims Embecta misrepresented the stability of its insulin pen needle business, leading to substantial investor losses. Investors who suffered losses between November 25, 2025, and May 4, 2026, have until August 17, 2026, to seek to become lead plaintiffs.
EMBC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Embecta Corp. to Contact the Firm Today!
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Embecta Corp. (NASDAQ:EMBC) and its officers for alleged federal securities law violations. The firm encourages investors who purchased Embecta securities between November 25, 2025, and May 4, 2026, to contact them, as the company is accused of making misleading statements regarding its business, operations, and prospects, specifically concerning its pen needle business and subsequent lowered fiscal guidance. Investors have until August 17, 2026, to request appointment as lead plaintiff.
Deadline Alert: Embecta Corp. (EMBC) Shareholders Who Lost
Glancy Prongay Wolke & Rotter LLP has issued a deadline alert for investors of Embecta Corp. (EMBC) who suffered losses. Shareholders who purchased securities between November 25, 2025, and May 4, 2026, are urged to contact the firm regarding a securities fraud lawsuit, with the lead plaintiff motion deadline set for August 17, 2026. The lawsuit alleges that Embecta made misleading statements about its financial outlook, particularly concerning declining pen needle sales, which led to a significant stock price drop after the company lowered its fiscal 2026 guidance.
Embecta Corp. (EMBC) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Glancy Prongay Wolke & Rotter LLP has announced a securities fraud class action lawsuit against Embecta Corp. (EMBC), urging investors who suffered losses to come forward. The lawsuit alleges that Embecta made misleading statements between November 25, 2025, and May 4, 2026, regarding its guidance and segment weakness, particularly in the U.S. pen needle market. Shareholders who purchased EMBC securities during this period have until August 17, 2026, to move for lead plaintiff status.
EMBC Investor Announcement: Embecta Sued on behalf of Investors to Recover Losses after Insulin Pen Issues Lead to 57% Stock Drop
A class action lawsuit has been filed against Embecta Corp. (NASDAQ: EMBC) and its executives for securities fraud. The lawsuit alleges that Embecta misled investors about the strength of its insulin pen needle product category, leading to a 57% stock drop after disappointing Q2 2026 results. Investors have until August 17, 2026, to apply to be a lead plaintiff in the case.
Kaplan Fox Encourages Investors of Embecta Corp. (NASDAQ: EMBC) to Contact the Firm Before Lead Plaintiff Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit follows a significant drop in Embecta's stock price after the company reported second-quarter fiscal 2026 results that were "significantly below expectations" and reduced its full-year revenue guidance. Investors are encouraged to contact Kaplan Fox before the lead plaintiff deadline of August 17, 2026.
EMBC Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Embecta Corp. Securities Lawsuit - Contact The Gross Law Firm
The Gross Law Firm has issued a shareholder alert for investors of Embecta Corp. (NASDAQ: EMBC) who purchased shares between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta made misleading statements regarding its fiscal results, specifically its pen needle business, prior to significantly missing expectations and lowering its 2026 fiscal guidance. Following this news, Embecta's stock price dropped over 57% in one day, and shareholders have until August 17, 2026, to seek lead plaintiff appointment.
Kaplan Fox Encourages Investors of Embecta Corp. (NASDAQ: EMBC) to Contact the Firm Before Lead Plaintiff Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. This action follows Embecta's disappointing Q2 2026 results and reduced fiscal 2026 revenue guidance, which caused a significant stock price drop. Investors are encouraged to contact Kaplan Fox before the lead plaintiff deadline of August 17, 2026.
Embecta Corp. Notice of August 17, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
Hagens Berman, a national shareholder rights law firm, is investigating Embecta Corp. (NASDAQ: EMBC) for alleged violations of federal securities laws after a class action lawsuit was filed. The lawsuit claims Embecta misrepresented the stability of its insulin pen needle business, leading to a significant stock price drop and dividend cut when the truth was revealed. Investors who suffered losses between November 25, 2025, and May 4, 2026, are encouraged to contact the firm before the August 17, 2026, lead plaintiff deadline.
EMBC INVESTOR ALERT: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) for alleged violations of federal securities laws, following a class action lawsuit claiming Embecta misrepresented the commercial stability of its insulin pen needle business. The lawsuit alleges the company's statements about its "stable" and "resilient" pen needle portfolio were false, as Embecta was experiencing significant competitive share loss and market volume softness. Investors who suffered substantial losses between November 25, 2025, and May 4, 2026, are encouraged to contact Hagens Berman to potentially lead the class action lawsuit.
Kaplan Fox Encourages Investors of Embecta Corp. (NASDAQ: EMBC) to Contact the Firm Before Lead Plaintiff Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit follows Embecta's Q2 2026 financial results, which significantly missed expectations, leading to a substantial drop in stock price. Investors are encouraged to contact Kaplan Fox before the lead plaintiff deadline of August 17, 2026.
Embecta adds to earnings rally with another 9% advance (EMBC:NASDAQ)
Embecta Corp. (EMBC) shares climbed another 9% on Monday, extending a rally initiated by the medical device company's strong quarterly earnings release. This surge brings the total rally to over 26% since the previous session, driven by better-than-expected non-GAAP EPS and revenue, and raised fiscal guidance. While analysts remain neutral due to competitive pressures, some investors are bullish on the stock's momentum and potential for a short-squeeze.
Embecta Q3 results beat analyst expectations
Embecta Corp. (Nasdaq: EMBC) reported Q3 results that surpassed analyst expectations, leading the company to raise its full-year adjusted earnings per share outlook. The medtech firm, specializing in insulin delivery, posted net income of $21.1 million on $271.7 million in revenue, with adjusted EPS of 56¢ significantly beating the 27¢ consensus. The improved performance was attributed to growth in the U.S. and International markets, as well as the acquisition of Owen Mumford.
Kaplan Fox & Kilsheimer LLP Alerts Embecta Corp. (NASDAQ: EMBC) Investors to a Securities Class Action Deadline on August 17, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Embecta Corp. (NASDAQ: EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta's management knew or recklessly disregarded weaknesses in the U.S. pen needle market, leading to disappointing Q2 2026 financial results and a significant drop in stock price. Investors are alerted to an August 17, 2026 deadline to serve as a lead plaintiff in the class action.
EMBC Stock – The Deadline to Move for Lead Plaintiff is
Robbins LLP has filed a securities class action lawsuit against Embecta Corp. (EMBC) on behalf of investors who purchased securities between November 25, 2025, and May 4, 2026. The lawsuit alleges that Embecta misled investors about its financial outlook, including its pen needle business and fiscal year 2026 revenue guidance, before significantly reducing its outlook and dividend. Investors who suffered losses and wish to serve as lead plaintiff must submit their papers to the court by August 17, 2026.
EMBC INVESTOR ALERT: Embecta Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) following a class action lawsuit alleging the company misled investors about the commercial stability of its insulin pen needle business. The lawsuit claims Embecta falsely assured investors of the business's strength while experiencing significant competitive losses and market softness. The truth reportedly emerged on May 5, 2026, leading to a massive revenue decline, a 43% cut in EPS guidance, and a 93% reduction in quarterly dividend, causing the stock to plummet 57.8%.
Embecta Number of Employees 2026 | Employee Count & Headcount Data
Embecta Corp. (EMBC) had approximately 1,829 employees worldwide as of March 2026, representing a 14.7% decline from 2023. Despite the overall headcount reduction, Embecta is actively hiring, with 143 active job postings in 2026, a 43.4% increase from 2025. The company's workforce is primarily concentrated in Northern Europe (38.0%) and North America (28.3%), with an average global salary of $89,856.
Embecta Corp. Notice of August 17, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
Hagens Berman is investigating Embecta Corp. (NASDAQ: EMBC) regarding alleged federal securities law violations after a class action lawsuit was filed. The lawsuit claims Embecta misrepresented the stability of its insulin pen needle business, leading to a significant stock price drop following a revenue decline and reduced financial guidance. Investors who suffered losses during the Class Period (Nov. 25, 2025 – May 4, 2026) are encouraged to contact Hagens Berman before the August 17, 2026, lead plaintiff deadline.
